MedTrace Logo

Molecularly Redefining Small Bowel Adenocarcinoma to Accelerate Precision Patient Care

NCT06234306 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2024-01-31

No results posted yet for this study

Summary

Small bowel adenocarcinoma is a rare malignancy, and there is limited knowledge about its optimal clinical management and molecular background. The SBAMOL study is an observational biomarker study that aims to identify prognostic and predictive biomarkers. This effort is intended to lay the groundwork for personalized medicine tailored to this specific patient group.

Conditions

  • Small Bowel Adenocarcinoma

Sponsors & Collaborators

  • Aarhus University Hospital

    collaborator OTHER

  • Rigshospitalet, Denmark

    collaborator OTHER

  • University of Copenhagen

    collaborator OTHER

  • Copenhagen University Hospital at Herlev

    lead OTHER

Principal Investigators

  • Dan Høgdall, MD PhD · Department of Oncology, Copenhagen University Hospital - Herlev and Gentofte

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-01
Primary Completion
2033-12-31
Completion
2033-12-31

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06234306 on ClinicalTrials.gov